The MNKD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MNKD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The MNKD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View MNKD Detailed Price Forecast - CNN Money||View MNKD Detailed Summary - Google Finance|
|View MNKD Detailed Summary - Yahoo! Finance||View MNKD Stock Research & Analysis - Zacks.com|
|View MNKD Trends & Analysis - Trade-Ideas||View MNKD Major Holders - Barrons|
|View MNKD Call Transcripts - NASDAQ||View MNKD Breaking News & Analysis - Seeking Alpha|
|View MNKD Annual Report - CompanySpotlight.com||View MNKD OTC Short Report - OTCShortReport.com|
|View MNKD Fundamentals - TradeKing||View MNKD SEC Filings - Bar Chart|
|View Historical Prices for MNKD - The WSJ||View Performance/Total Return for MNKD - Morningstar|
|View the Analyst Estimates for MNKD - MarketWatch||View the Earnings History for MNKD - CNBC|
|View the MNKD Earnings - StockMarketWatch||View MNKD Buy or Sell Recommendations - MacroAxis|
|View the MNKD Bullish Patterns - American Bulls||View MNKD Short Pain Metrics - ShortPainBot.com|
|View MNKD Stock Mentions - StockTwits||View MNKD Stock Mentions - PennyStockTweets|
|View MNKD Stock Mentions - Twitter||View MNKD Investment Forum News - Investor Hub|
|View MNKD Stock Mentions - Yahoo! Message Board||View MNKD Stock Mentions - Seeking Alpha|
|View Insider Transactions for MNKD - SECform4.com||View Insider Transactions for MNKD - Insider Cow|
|View MNKD Major Holdings Summary - CNBC||View Insider Disclosure for MNKD - OTC Markets|
|View Insider Transactions for MNKD - Yahoo! Finance||View Institutional Holdings for MNKD - NASDAQ|
|View MNKD Stock Insight & Charts - FinViz.com||View MNKD Investment Charts - StockCharts.com|
|View MNKD Stock Overview & Charts - BarChart||View MNKD User Generated Charts - Trading View|
MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target
Posted on Tuesday December 11, 2018
Zacks SCR analysts Brian Marckx, CFA and Anita Dushyanth, PhD have initiated coverage of MannKind Corporation with a $4.25/share price target. MannKind Corporation (MNKD) was founded in the early 2000’s by the late Alfred Mann, a physicist by training, Mann was a pioneer in several fields including aerospace, electronics and medical devices. Among his successes prior to MannKind was development of the first rechargeable pacemaker and MiniMed, a revolutionary miniaturized insulin pump that was sold to Medtronic in 2001 for more than $3B.
Biotech Stocks Beating the Market
Posted on Monday December 10, 2018
HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Here are several biotech plays to pay close attention to in the coming sessions. Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), MannKind ...
MannKind Appoints Christine Mundkur to its Board of Directors
Posted on Tuesday November 27, 2018
MannKind Corporation (MNKD) today announced that Christine Mundkur has joined its Board of Directors, effective November 27, 2018. Ms. Mundkur will also serve as a member of the Audit Committee of the Board. Ms. Mundkur brings 25 years of experience in the pharmaceutical industry to the MannKind Board. “Christine brings a tremendous wealth of experience to our board of directors,” said Kent Kresa, Chairman of the Board of MannKind Corporation.
Analysts: Why United Therapeutics has had a streak of licensing deals
Posted on Tuesday November 27, 2018
United Therapeutics Corp. has been striking more licensing deals this year, a trend some analysts say illustrates the company’s strategy to staying ahead of generic competition. The Silver Spring drugmaker announced a global licensing agreement earlier this month with California company Arena Pharmaceuticals Inc. (NASDAQ: ARNA). United Therapeutics (NASDAQ: UTHR) will pay Arena $800 million upfront, plus up to $400 million in milestone payments, for exclusive rights to ralinepag, a phase 3 investigational drug candidate in development for pulmonary arterial hypertension.